Deriving Absolute Bioavailability From Dose-Normalized AUC

Why AUC Can Compare Routes

An extravascular dose does not necessarily reach systemic circulation in full. Some drug may not be absorbed, or may be lost before reaching the circulation. Absolute bioavailability, denoted $F$, describes the fraction of the administered dose that reaches systemic circulation unchanged. An intravenous dose enters systemic circulation directly and therefore provides the reference $F=1$.

The connection between bioavailability and systemic exposure follows from a mass balance. Under the appropriate conditions, the area under the plasma concentration–time curve, or AUC, is proportional to the amount of drug entering the systemic circulation. The proportionality factor is clearance. Comparing AUC per unit dose after extravascular and intravenous administration can therefore isolate $F$, because the same clearance applies to both measurements and cancels in their ratio.

Definition: Let $D_{\mathrm{EV}}$ be the administered extravascular dose and $D_{\mathrm{IV}}$ the administered intravenous dose. Let $\mathrm{AUC}_{\mathrm{EV},0-\infty}$ and $\mathrm{AUC}_{\mathrm{IV},0-\infty}$ denote complete AUCs for the same drug measured in the same way. When systemic clearance is the same for both administrations, absolute bioavailability is $$ F = \frac{\mathrm{AUC}_{\mathrm{EV},0-\infty}/D_{\mathrm{EV}}} {\mathrm{AUC}_{\mathrm{IV},0-\infty}/D_{\mathrm{IV}}}. $$

Deriving the Dose-Normalized AUC Equation

Write $CL$ for systemic clearance: the proportionality constant between plasma concentration and the rate at which drug is eliminated from systemic circulation. The standard AUC relationship requires linear, time-invariant disposition over the concentration range being compared, so that the elimination rate is $CL\,C(t)$ with the same $CL$ throughout the profile. Assume the drug concentration is measured before dosing at baseline and the complete profile is followed until the drug from that dose has been eliminated.

For an extravascular dose, the total amount of unchanged drug entering systemic circulation is $F D_{\mathrm{EV}}$. Integrating the mass balance over the complete profile equates this systemic input to total elimination. Since the elimination rate is $CL\,C(t)$, its integral is $CL$ times the complete AUC:

F D_{\mathrm{EV}} = CL\int_0^\infty C_{\mathrm{EV}}(t)\,dt = CL\,\mathrm{AUC}_{\mathrm{EV},0-\infty}.

Rearranging gives the exposure after extravascular administration. For an intravenous dose, the complete administered dose enters systemic circulation, so the same mass balance has $D_{\mathrm{IV}}$, rather than $F D_{\mathrm{EV}}$, on the left:

\mathrm{AUC}_{\mathrm{EV},0-\infty} = \frac{F D_{\mathrm{EV}}}{CL}, \qquad \mathrm{AUC}_{\mathrm{IV},0-\infty} = \frac{D_{\mathrm{IV}}}{CL}.

Divide each expression by its administered dose. Both dose-normalized AUCs contain the same factor $1/CL$; taking their ratio removes it:

\frac{\mathrm{AUC}_{\mathrm{EV},0-\infty}/D_{\mathrm{EV}}} {\mathrm{AUC}_{\mathrm{IV},0-\infty}/D_{\mathrm{IV}}} = \frac{F/CL}{1/CL} = F.

This cancellation is the key result. It does not mean clearance is unimportant: each AUC depends on clearance. Rather, clearance does not need to be known if it is the same for the two administrations. AUC divided by dose has units of time per volume, such as hours per litre; the ratio of two such quantities is dimensionless, as a fraction should be.

Conditions for a Valid Comparison

The derivation states what must be true for the equation to estimate absolute bioavailability. These conditions concern the drug, the exposure measurement, and the comparison between administrations.

Clearance is common to both administrations. The same drug and analyte must be studied under conditions where systemic clearance is unchanged. A route comparison in a stable subject is one way to support this condition; a change in disease state, interacting medication, or time-dependent clearance can undermine it.
The AUC represents the complete profile. The relevant quantity is $\mathrm{AUC}_{0-\infty}$, not merely the AUC over an arbitrarily chosen early interval. If the terminal portion is missed, the measured area may not represent total exposure.
Drug from the dose is the source of the measured exposure. Residual drug from an earlier dose or another source can add concentration to the profile. Appropriate washout and baseline assessment help avoid attributing that exposure to the dose under study.
The intravenous reference delivers the administered dose systemically. This is why its bioavailability is set to one in the definition.
Disposition is linear and stable over the profiles. The elimination rate must be representable as the same $CL$ multiplied by concentration. If clearance changes with concentration or over time, the factor cannot generally be taken outside the AUC integral and cancelled in this way.

The equation does not require extravascular absorption to be instantaneous or complete. The absorption rate can change the shape and timing of the concentration–time curve without changing the total AUC under the stated conditions. Any loss before systemic entry is reflected in $F$, rather than being mistaken for a change in systemic clearance.

Worked Example: Seeing Clearance Cancel

Consider a hypothetical drug with $CL=5.00$ L/h. Suppose a 100 mg intravenous dose produces a complete AUC of $20.0$ mg·h/L. For illustration, suppose an extravascular dose of the same size has $F=0.400$, with the same clearance.

The intravenous prediction is $$ \mathrm{AUC}_{\mathrm{IV},0-\infty} = \frac{100\ \mathrm{mg}}{5.00\ \mathrm{L/h}} = 20.0\ \mathrm{mg\cdot h/L}. $$

The amount entering systemic circulation after the extravascular dose is $F D_{\mathrm{EV}}=0.400(100\ \mathrm{mg})=40.0$ mg. Its predicted AUC is $$ \mathrm{AUC}_{\mathrm{EV},0-\infty} = \frac{40.0\ \mathrm{mg}}{5.00\ \mathrm{L/h}} = 8.00\ \mathrm{mg\cdot h/L}. $$

The dose-normalized AUC ratio is $$ \frac{8.00/100}{20.0/100} = 0.400. $$ The units in each normalized AUC are h/L, so they cancel in the ratio. The result recovers the stipulated $F=0.400$. This illustration assumes complete AUCs and the same $CL$ for both profiles; if either condition fails, the cancellation argument does not apply as written.

Interpreting the Equation and Its Limits

When both doses are the same, the equation reduces to the ratio of the two AUCs. When doses differ, raw AUCs alone do not give the dose-normalized comparison: AUC must first be divided by its own administered dose. The governing result is the ratio of dose-normalized AUCs, not simply “extravascular AUC divided by intravenous AUC.”

This ratio method is useful because it does not require a separate estimate of clearance. A conceptually equivalent alternative, if $CL$ were independently known and applicable, would be to use $F=CL\,\mathrm{AUC}_{\mathrm{EV},0-\infty}/D_{\mathrm{EV}}$. The route-ratio approach avoids needing that numerical clearance value, but it replaces that requirement with the assumption that clearance is common across the two administrations.

An estimate of $F$ is specific to the drug, route, and conditions of the comparison. The equation alone does not show whether a value reflects incomplete absorption, presystemic loss, or both. Nor does it guarantee that a value obtained at one dose applies at another dose: the derivation requires stable disposition, and extrapolating a dose-normalized comparison across doses also requires that the relevant bioavailability does not change with dose.

Worked Example: Why Raw AUCs Can Mislead

In a hypothetical comparison, an intravenous dose of 80 mg gives a complete AUC of 16.0 mg·h/L. An extravascular dose of 160 mg gives a complete AUC of 24.0 mg·h/L. Assume the measurements concern the same analyte and that systemic clearance is common to the two administrations.

The raw AUC ratio is $24.0/16.0=1.50$. That number is not the bioavailability, because the extravascular dose is twice the intravenous dose. Normalize each AUC by its own dose: $$ \frac{\mathrm{AUC}_{\mathrm{EV},0-\infty}/D_{\mathrm{EV}}} {\mathrm{AUC}_{\mathrm{IV},0-\infty}/D_{\mathrm{IV}}} = \frac{24.0\ \mathrm{mg\cdot h/L}/160\ \mathrm{mg}} {16.0\ \mathrm{mg\cdot h/L}/80\ \mathrm{mg}} = \frac{0.150}{0.200} = 0.750. $$

Thus, under the stated assumptions, the dose-normalized comparison estimates $F=0.750$. The raw ratio exceeded one because it also reflected the larger extravascular dose; it was not an estimate of the fraction of dose reaching systemic circulation.

Worked Example: When Clearance Does Not Cancel

Suppose, hypothetically, that an extravascular dose $D$ has $F=0.500$ and clearance $CL_{\mathrm{EV}}=10.0$ L/h, while the intravenous reference is measured under a different condition with $CL_{\mathrm{IV}}=5.00$ L/h. For simplicity, take both doses to be 100 mg and assume complete AUCs.

The predicted AUCs are $$ \mathrm{AUC}_{\mathrm{EV},0-\infty} = \frac{0.500(100\ \mathrm{mg})}{10.0\ \mathrm{L/h}} = 5.00\ \mathrm{mg\cdot h/L}, \qquad \mathrm{AUC}_{\mathrm{IV},0-\infty} = \frac{100\ \mathrm{mg}}{5.00\ \mathrm{L/h}} = 20.0\ \mathrm{mg\cdot h/L}. $$

The dose-normalized ratio is $(5.00/100)/(20.0/100)=0.250$, not the true $F=0.500$. Algebraically, when clearances differ, the ratio is $$ \frac{\mathrm{AUC}_{\mathrm{EV},0-\infty}/D_{\mathrm{EV}}} {\mathrm{AUC}_{\mathrm{IV},0-\infty}/D_{\mathrm{IV}}} = F\frac{CL_{\mathrm{IV}}}{CL_{\mathrm{EV}}}. $$

Here $CL_{\mathrm{IV}}/CL_{\mathrm{EV}}=0.500$, which halves the result. The comparison fails because the two profiles do not share a clearance; dose normalization alone cannot repair that difference.

Diagnostics and Common Pitfalls

Before interpreting a dose-normalized AUC ratio as absolute bioavailability, check that the data and study conditions support the derivation. Confirm that both AUCs cover the same analyte and are intended to represent complete systemic exposure. Examine whether the terminal profile is sufficiently characterized to estimate the remaining area, and whether baseline concentrations or carryover could add exposure unrelated to the dose being evaluated. Consider whether the comparison conditions plausibly preserve the same systemic clearance.

A common mistake is to say, “The extravascular AUC is half the intravenous AUC, so bioavailability is 50%,” without checking the doses. This reasoning is valid only if the doses are equal and clearance is common. In general, divide each AUC by its own dose first, then compare those normalized values. A second mistake is to assume that any difference in AUC must arise from absorption. A change in clearance can also change AUC, which is why the clearance assumption is essential rather than a technical detail.

A result above one is not, by itself, proof that the algebra is wrong. It should prompt a review of the dose records, AUC estimation, analyte, clearance comparability, and model assumptions. The equation identifies what the ratio estimates under its conditions; it does not guarantee that the conditions held in a particular comparison.

Key takeaway: Under linear, stable disposition with common systemic clearance and complete AUCs, $\mathrm{AUC}_{0-\infty}=F D/CL$ after extravascular dosing and $\mathrm{AUC}_{0-\infty}=D/CL$ after intravenous dosing. Their dose-normalized ratio is absolute bioavailability because clearance cancels.

Check Your Understanding

Answer each question using the assumptions stated in the question. Solutions follow the problems.

In one sentence, explain why the intravenous reference has $F=1$ in the derivation.
A hypothetical 120 mg intravenous dose gives a complete AUC of 24.0 mg·h/L. With the same clearance, what AUC does the model predict for a 120 mg extravascular dose with $F=0.250$?
Two complete AUCs are measured after equal doses, but clearance is twice as high during the extravascular administration as during the intravenous administration. Does the dose-normalized ratio equal $F$? Explain.
Why is an AUC measured only over an early time interval not automatically interchangeable with $\mathrm{AUC}_{0-\infty}$ in the derivation?

Solutions. (1) The entire administered intravenous dose enters systemic circulation, so the fraction reaching it unchanged is one by definition. (2) The intravenous data imply $CL=120/24.0=5.00$ L/h. The predicted extravascular AUC is $0.250(120)/5.00=6.00$ mg·h/L. (3) No. The ratio is $F(CL_{\mathrm{IV}}/CL_{\mathrm{EV}})$; if $CL_{\mathrm{EV}}=2CL_{\mathrm{IV}}$, it equals $F/2$. (4) The early interval omits any later exposure. The mass-balance derivation uses the integral over the complete profile, so an early partial AUC does not generally equal the total AUC required by the equation.